These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16312311)

  • 1. Kinetics of antimicrobial activity of amoxycillin/clavulanic acid against Bacteroides fragilis group.
    García-Rodriguez JA; Garcia Sanchez JE; Munoz Bellido JL; Trujillano I
    J Chemother; 1989 Jul; 1(4 Suppl):76-7. PubMed ID: 16312311
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetics of antimicrobial activity of amoxicillin/clavulanic acid and metronidazole against beta-lactamase-producing Bacteroides fragilis group.
    García-Rodríguez JA; García Sánchez JE; Trujillano I; Muñoz-Bellido JL
    J Chemother; 1990 Feb; 2(1):11-6. PubMed ID: 2332779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriological studies of amoxycillin-clavulanic acid against anaerobic bacteria.
    Lupo G; Lo Bue AM; Chisari G; Blandino G; Gismondo MR
    J Chemother; 1989 Jul; 1(4 Suppl):74-5. PubMed ID: 16312310
    [No Abstract]   [Full Text] [Related]  

  • 4. The in-vitro susceptibility of the Bacteroides fragilis group to amoxycillin-clavulanic acid.
    Brown EM
    J Antimicrob Chemother; 1984 Oct; 14(4):367-72. PubMed ID: 6501130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clavulanic acid-potentiated activity of amoxicillin against Bacteroides fragilis.
    Indiveri MC; Hirsh DC
    Am J Vet Res; 1985 Oct; 46(10):2207-9. PubMed ID: 4062030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of standardization of in-vitro susceptibility testing of the Bacteroides fragilis group to amoxycillin-clavulanic acid.
    Brown EM
    J Antimicrob Chemother; 1991 Jul; 28(1):147-9. PubMed ID: 1769936
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro antibacterial activity of cefotetan against Bacteroides fragilis group clinical isolates.
    Menozzi M; Avanzini P; Lecchini R; Bigi M; Chezzi C
    Chemioterapia; 1987 Jun; 6(2 Suppl):88-91. PubMed ID: 3509541
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.
    Betriu C; Sánchez A; Palau ML; Gómez M; Picazo JJ
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2372-4. PubMed ID: 11451700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of amoxycillin and benzylpenicillin combined with clavulanic acid against Bacteroides fragilis in vitro and in experimentally infected mice.
    Dijkmans BA; Vaishnav J; Mattie H
    Scand J Infect Dis; 1985; 17(3):311-21. PubMed ID: 3903976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of clavulanic acid on the activities of ten beta-lactam agents against members of the Bacteroides fragilis group.
    Lamothe F; Auger F; Lacroix JM
    Antimicrob Agents Chemother; 1984 May; 25(5):662-5. PubMed ID: 6732233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbapenem resistance in Bacteroides fragilis.
    Ang L; Brenwald NP; Walker RM; Andrews J; Fraise A
    J Antimicrob Chemother; 2007 May; 59(5):1042-4. PubMed ID: 17363423
    [No Abstract]   [Full Text] [Related]  

  • 13. [In vitro activity of 9 antimicrobials against Bacteroides fragilis].
    Betriu Cabecerán C; Cogollos Agruña R; García Alonso G; Agra Valero M
    Rev Clin Esp; 1988 Feb; 182(3):134-6. PubMed ID: 3285381
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antibiotic sensitivity of Bacteroides fragilis group in Algeria].
    Merad AS; Ghemati M; Faid N; Kimouche N
    Arch Inst Pasteur Alger; 1998; 62():91-110. PubMed ID: 11256322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of amoxycillin/clavulanic acid (augmentin) against polymicrobial Bacteroides fragilis/Escherichia coli infections in the mouse.
    Beale AS; Gisby J; Sutherland R
    J Chemother; 1989 Jul; 1(4 Suppl):78-9. PubMed ID: 16312312
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bacteroides fragilis group in non-diarrheal human feces and its antimicrobial susceptibility].
    Rodríguez E; Gamboa MM; Rodríguez C; Vargas P
    Rev Esp Quimioter; 2006 Dec; 19(4):357-62. PubMed ID: 17235405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of SMAP-29 against the Bacteroides fragilis group and clostridia.
    Arzese A; Skerlavaj B; Tomasinsig L; Gennaro R; Zanetti M
    J Antimicrob Chemother; 2003 Sep; 52(3):375-81. PubMed ID: 12917245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibility to antimicrobial drugs of enterotoxin producing strains of Bacteroides fragilis isolated from different countries].
    Obuch-Woszczatyński P; Rokosz A; Sawicka-Grzelak A; Pituch H; Meisel-Mikołajczyk F; Łuczak M
    Med Dosw Mikrobiol; 2002; 54(3):253-8. PubMed ID: 12632660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sensitivity of Bacteroides of the fragilis group to various antibiotics].
    de la Torre Misiego F; Betriú Cabecerán C; López Bartolomé O; Rodriguez Avial C; López Doriga
    Rev Clin Esp; 1981 Dec; 163(6):387-90. PubMed ID: 7342200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.